OPK — OPKO HEALTH, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 944809 ·
Last close
$1.63
Market Cap
$1.22B
52W High
$1.75
52W Low
$0.98
ADV30
2,808,489
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 163,580,000 | 80,017,000 | -25,042,000 | -8,416,000 | 1,829,453,000 | 300,761,000 | 645,287,000 |
| Mar 2026 | 124,196,000 | 45,755,000 | -51,017,000 | -54,848,000 | 1,856,796,000 | 341,881,000 | 652,186,000 |
| Dec 2025 | 148,450,000 | 64,025,000 | -38,317,000 | -31,257,000 | 1,931,944,000 | 369,074,000 | 663,985,000 |
| Sep 2025 | 151,669,000 | 49,893,000 | -53,520,000 | 21,631,000 | 1,995,508,000 | 415,198,000 | 690,018,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,378,000
Investing CF
$206,338,000
Financing CF
$-52,728,000
CapEx
$-10,638,000
Dividends Paid
—
Buybacks
$-46,572,000
EPS Diluted TTM
$-0.09
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,353,954,000
Inventory
$61,851,000
Receivables
$114,914,000
ST Investments
—
EBIT TTM
$-34,838,000
Pretax Income TTM
$-79,825,000
Interest Exp TTM
$44,987,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$587,897,024
EBITDA
$-78,172,000
Free Cash Flow
$54,760,376
Enterprise Value
$1,269,057,280
Total Cash
$300,760,992
Total Debt
$398,083,008
Shares Out
746,328,225
Trailing EPS
$-0.07
Book Value
$1.59
ROE
-5.9%
ROA
-5.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 606,879,000 | -218,985,000 | -225,680,000 | 1,931,944,000 | 663,985,000 | 1,267,959,000 | -178,542,000 |
| Dec 2024 | 713,142,000 | -273,558,000 | -53,224,000 | 2,200,212,000 | 834,764,000 | 1,365,448,000 | -183,489,000 |
| Dec 2023 | 863,495,000 | -158,057,000 | -188,863,000 | 2,011,698,000 | 622,479,000 | 1,389,219,000 | -28,197,000 |
| Dec 2022 | 1,004,196,000 | -246,124,000 | -328,405,000 | 2,167,259,000 | 605,611,000 | 1,561,648,000 | -95,189,000 |
TTM Snapshot
Revenues TTM
$1,371,868,000
NetIncome TTM
$-64,984,000
OpCashFlow TTM
$0
Assets (Latest)
$2,167,259,000
Forward EPS
$-0.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | $1.22B | $37.89 | — |
| BCAX | Bicara Therapeutics Inc. | $1.24B | $18.80 | — |
| EVOTF | Evotec SE | $1.19B | $6.69 | — |
| HROW | HARROW, INC. | $1.18B | $31.60 | — |
| AVLN | Avalyn Pharma Inc. | $1.26B | $28.32 | — |
News headlines (Yahoo Finance, 1h cache)
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
2026-09-21 13:33 · Yahoo
The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy
2026-09-16 00:18 · Yahoo
OPKO Health (OPK) Cashes In A Future Royalty Stream Early
2026-09-14 03:07 · Yahoo
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
2026-09-11 05:02 · Yahoo
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
2026-08-26 15:30 · Yahoo
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
2026-08-24 15:15 · Yahoo
OPK Raises $125 Million Against Royalties: What Investors Should Know
2026-08-19 16:50 · Yahoo
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
2026-08-19 16:35 · Yahoo
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
2026-08-18 17:23 · Yahoo
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
2026-08-13 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.